ABSTRACT
Ertapenem (formerly MK-0826; Merck) is a once-daily parenteral beta-lactam antibiotic licensed in the USA in November 2001 and in Europe in April 2002. Generally, ertapenem has substantial activity against Enterobacteriaceae-producing extended-spectrum beta-lactamases (ESBLs) and AmpC beta-lactamases (Hammond, 2004; Wexler, 2004).
